(NASDAQ: INBX) Inhibrx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.06%.
Inhibrx Biosciences's earnings in 2026 is -$130,185,000.On average, 4 Wall Street analysts forecast INBX's earnings for 2026 to be -$124,310,426, with the lowest INBX earnings forecast at -$160,312,049, and the highest INBX earnings forecast at -$84,171,528. On average, 4 Wall Street analysts forecast INBX's earnings for 2027 to be -$91,030,308, with the lowest INBX earnings forecast at -$134,863,410, and the highest INBX earnings forecast at -$42,917,620.
In 2028, INBX is forecast to generate -$61,108,424 in earnings, with the lowest earnings forecast at -$103,807,444 and the highest earnings forecast at -$14,589,027.